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Adefovir dipivoxil treatment has signiﬁcantly improved the outcome of chronic hepatitis B virus (HBV) infection. However, it
remains largely unknown how immune system responds to the treatment. Chronic HBV patients were treated with adefovir
dipivoxil and examined for serum HBV DNA loads, cytokines, and T helper (Th1) and 2 (Th2) cytokine producing T cells during
104 weeks of the treatment. Th1/Th2 cytokines producing T cells were signiﬁcantly lower in chronic HBV patients as compared to
normal individuals. Adefovir dipivoxil treatment led to the increase of Th1/Th2 cytokines producing T cells and serum cytokine
levels in association with the decline of HVB DNA load. In contrast, Th1/Th2 cytokines producing T cells remained lower in one
patient detected with adefovir dipivoxil resistant HBV A181T/V mutation. This study has established inverse correlation of the
increase of Th1/Th2 immunity and the decline of HBV DNA load in chronic HBV patients during adefovir dipivoxil treatment.
1.Introduction
Chronic HBV infection is one of the most common infec-
tious diseases and contributes to a million death per year
worldwide [1]. China is among the highly endemic countries
with approximately 8% of the population being chronically
infected with the virus [2]. In the last decade, clinical man-
agementofchronicHBVinfectionhassigniﬁcantlyimproved
mainly due to the introduction of nucleoside and nucleotide
analogs [3]. Lamivudine is the ﬁrst approved nucleoside
analog that has been clinically proved to be capable of
inhibiting HBV replication, enhancing the seroconversion of
hepatitis B e antigen (HBeAg) to antibody (HBeAb), and
delaying the progression of the HBV-related complications
[4–6]. However, prolonged treatment with lamivudine is
limited by the emergence of HBV mutations and thereby
drug resistance in up to 67% of patients [7].
Adefovir dipivoxil is a nucleotide analog of adenosine
monophosphate [8, 9] that is converted intracellularly to
the active metabolite, adefovir diphosphate, which can
inhibit DNA polymerase of both wild-type HBV and
lamivudine-resistant HBV mutant [10]. Randomized trials
have proved the eﬀectiveness of adefovir dipivoxil in treating
HBeAg-positive [11–13] and HBeAg-negative chronic HBV
patients [14, 15]. Adefovir dipivoxil resistance due to the
mutationsintheDNApolymeraseofHBV[16]wasobserv ed
only in 18% HBeAg-negative [17] and 20% HBeAg-positive
chronic HBV patients treated up to four years [12]. In
contrast, however, a multicenter randomized trial in Chinese
patients has shown no drug resistance during the four years
treatment [18].
T-cell immunity plays a critical role in determining the
outcome of HBV infection [19]; however, it remains to
be established how immune system responds to adefovir
dipivoxil and thereby contributes to sustained viral control
and improved liver function. In acute HBV infection, CD8
cytotoxic T and CD4 helper T-cells-mediated immunities are
activated and involved in the clearance of HBV from the
hepatocytes [20]. In chronic HBV infection, however, CD8
and CD4 T-cell immunity are hyporesponsive in association
with persistent HBV serum load [21], which suggests that
high HBV load may impair T-cell immunity and antiviral
treatments can improve the immunity by reducing viral load
[19]. In support of this, lamivudine therapy has been proven
to reduce HBV serum load and restore CD4 T-cell immunity
in chronic HBV patients [22, 23].2 Mediators of Inﬂammation
Recent studies have further shown that adefovir dipivoxil
treatment leads to the seroclearance of HBV DNA and the
recovery of CD4 [24, 25] but not CD8 T-cell immunity in
chronic HBV patients [25]. Th1 cells are characterized by
their capability of producing Th1 cytokines, interferon-γ
(IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-α
(TNF-α) whereas Th2 cells are able to synthesize the Th2
cytokines IL-4 and IL-10 [26]. In this paper, we report that
a long-term treatment with adefovir dipivoxil leads to the
decline of HBV DNA load and the increase of Th1/Th2
immunity in chronic HBV patients in China.
2. Patientsand Methods
2.1. Patients. A total of 22 CHB (1 7m e na n d5w o m e n )
patients who were presented to the Jilin University First
Hospital and 20 healthy controls were included in the
study. These patients were treated with adefovir dipivoxil
(Gilead Science, Forster City, CA, USA) 10mg orally once
daily for 104 weeks. Th1 and Th2 cytokines including
IL-2, IFN-γ,T N F - α, IL-4, and IL-10 were measured before
and at 12, 24, 36, 52, 65, 78, 92, and 104 weeks after
treatment. Viral suppression was evaluated by measurement
of HBV DNA along with biochemical markers, AST and
ALT. During the followup, one and then three patients
dropped out, respectively, at the 36th and 78th weeks
of the treatment. The study was approved by the First
Hospital Ethical Committee of Jilin University and carried
out according to the 1975 Declaration of Helsinki. All
patients provided written informed consent prior to study
enrollment.
2.2. Flow Cytometric Analysis of Intracellular Cytokine Stain-
ing (ICS). Venous blood samples were collected from
chronicHBVpatientsbefore(0week)andafterthetreatment
with adefovir dipivoxil for 12, 24, 36, 52, 65, 78, 92,
and 104 weeks. Blood cells were stimulated and cytokine-
secreting cells were analyzed using ﬂow cytometry accord-
ing to previously reported protocol [27]. For the analysis
of intracellular cytokines production, 1000μL blood was
diluted with Iscove’s modiﬁed Dulbecco’s medium (1:1
volume). The diluted whole blood was stimulated with
phorbol 12-myristate 13-acetate (PMA; Sigma Chemical
C o . ,S t .L o u i s ,M O )( 5 0n g / m L )p l u s2μg/mL of ionomycin
for 6 hours. 10μg/mL brefeldin A was added at 2 hours
before the cells were collected and stained with antibodies.
All antibodies were purchased from BD Biosciences (BD
Bioscience, Heidelberg, Germany). After being stained with
10μL antibodies to surface markers (anti-CD3-PerCP, anti-
CD8-FITC, or anti-CD8-PE). The cells were permeabilized
and ﬁxed using ﬁxing reagent (Caltag, US) and rupture of
membrane and the dissolution of blood reagent (Caltag,
US) according to the manufacturer’s instructions. The
anti-IL-2-FITC, anti-TNF-α-FITC, anti-IL-4-PE, anti-IFN-
γ-PE or isotope-matched control antibodies were added
for 30 minute. All the samples were analyzed using a
FACSCalibur instrument (FACSCalibur, Beckton Dickinson)
and FlowJo software. At least 20,000 events per run were
acquired.
2.3. Cytometric Bead Array of Serum Th1 and Th2 Cytokines.
Serum cytokine levels were determined by cytometric bead
array (CBA) [28], based on the manufacturer’s protocol
(CBA, BD Biosciences, San Joes, CA). The protocol was
modiﬁed based on the earlier report to measure cytokines in
25μLs e r u m[ 29]. The amount of cytokines was quantiﬁed
using the cytometric bead array kit on a FACSCalibur
cytometry (BD Biosciences) equipped with CellQuestPro
and CBA software (Becton Dickinson).
2.4. Hepatitis Serology and HBV Mutation Analysis. Serum
HBsAg,HBsAb,HBeAg,HBeAb,andhepatitisBcoreantigen
antibody (HBcAb) were examined by commercial MURES
Mikrotiterplatten enzyme immunoassays according to the
manufacturer protocol (Abbott Laboratories, Abbott Park,
US). HBsAg quantitation was performed by automated
chemiluminescent microparticle immunoassay [30], based
onthemanufacturer’sprotocol(AbbottLaboratories,Abbott
Park, IL). Serum HBV DNA was measured by quantitative
PCR assay using luciferase quantitation detection kit (Roche
Amplicor, limit of quantiﬁcation 300 copies/mL). Serum
HBV DNA was examined for mutations using HBV Drug
Resistant Mutations Assay (Gene Tech Company Limited,
Shanghai, China) [31]. In brief, serum HBV DNA was
ampliﬁed by PCR and pyrosequenced to detect the following
mutations of HBV polymerase: I169T, V173L, L180M,
A181V/T, T184G/S/A/C, A194T, S202G/I, M204V/I, N236T,
and M250V.
2.5. Statistical Analysis. All clinical and ﬂow cytometry data
were compared using Wilcoxon rank sum test and Chi-
square test. SAS version 8.0 software was used. Correlations
were determined using Spearman’s correlation test. Results
are given in median (range), unless speciﬁed otherwise.
For all tests, value of P<. 05 was considered statistically
signiﬁcant.
3. Results
3.1. Demographic Background. Twenty-two Chinese patients
(17 men and 5 women) were enrolled in the study after
initiating screening of HBV serology and liver biochemistry
(Table 1). The ages of these patients ranged from 30 to 61
years old (average age at 45.9 ± 8.1) with 10.3 ± 1.6y e a r s
of clinical history of chronic HBV infection. Initial screening
of serum hepatitis virology detected HBsAg, HbeAb, and
HBV DNA in all patients with an average HBV DNA load
at 5.8 ± 0.2log10 copies/ml. Biochemical analysis of serum
revealed elevated ALT and AST, respectively, at the median
of 27.6 (10.1–445.6) and 26.8 (7.1–312.4) units/L in all
the patients. In contrast, twenty health volunteers were
serologicallynegativeforHbsAg,HbeAb,andHBVDNAand
biochemically normal for ALT and AST.
3.2. Th1 and Th2 Cytokine Producing CD3+CD4+ T-Cells at
Baseline in Chronic HBV Patients. The results revealed the
baseline levels of Th1 and Th2 cells producing IL-2, IFN-γ,
TNF-α, IL-4, and IL-10, respectively, at the median of 12.16,
5.73, 15.75, 5.69, and 11.7 in the health volunteers (Table 2).Mediators of Inﬂammation 3
Table 1: Demographic proﬁles of study participants.
Parameters Chronic HBV
patients
Health
volunteers
No. 22 20
Age (years)
Mean±SD 45.9 ±8.13 8 .5 ±11.8
∗
Median 46 36.5
Range 30–61 25–58
Sex N(%)
Male 17 (77.3) 14 (70)
Female 05 (22.7) 6 (30)
Years from HBV diagnosis
Mean±SD 10.3 ±1.6N A
HBV DNA (log10 copies/ml)
Mean 5.8 NA
SD 0.2
ALT (U/L)
Median 27.6 15.4∗
Range 10.1–445.6 5.6–37.5
AST (U/L)
Median 26.8 11.3∗
Range 7.1–312.4 2.5–25.4
HbsAg (log10 IU/ml)
Median 1082.5 NA
Range 90.0–12795.0
∗Diﬀerences between treatment groups and health volunteers were statisti-
cally signiﬁcant (P<. 5).
In contrast, however, both Th1 and Th2 cytokine-producing
CD3+CD4+ T-cells were detected at very lower levels in
the chronic HBV patients with the median of cytokine-
producing cells at 0.6 (IL-2), 0.4 (IFN-γ), 0.7 (TNF-α), 0.4
(IL-4),and0.6(IL-10).Thisstudyfurtherconﬁrmsthatboth
Th1 and Th2 immunity are functionally impaired in chronic
HBV patients.
3.3. Response of Th1/Th2 Cytokine-Producing T-Cells to Ade-
fovir Dipivoxil Treatment. CD3+CD4+ T-cells were gated
and examined by intracellular staining of Th1 (IL-2, IFN-γ,
TNF-α) and Th2 cytokines (IL-4, IL-10) (Figure 1). Prior to
adefovir dipivoxil treatment, Th1 (IL-2, IFN-γ,T N F - α)a n d
Th2 cytokines (IL-4, IL-10) producing CD3+CD4+ T-cells
were signiﬁcantly lower in chronic HBV patients as com-
pared to healthyindividuals (Table2).Four patients dropped
out the study. Of the remaining eighteen patients in the
study, sixteen showed no HBV mutations, whereas one had
lamivudine resistant HBV M204V/I mutation and another
showed adefovir dipivoxil resistant HBV A181T/V mutation.
Adefovir dipivoxil treatment resulted in the increase of
both Th1 and Th2 cytokines-producing CD3+CD4+ T-
cells in all the patients without HBV mutations throughout
the treatment (Table 3). Statistic analysis with SAS 8.0
software revealed a signiﬁcant relationship (P<. 05)
Table 2: Comparison of intracellular Th1/Th2 cytokines in chronic
HBV patients and healthy volunteers.
Parameters
(% CD3+CD4+) Patients (no. 22) Healthy volunteers
(no. 20) P value
IL-4 0.4 (0–6.0) 5.69 (1.99–14.22) <.0001
IFN-γ 0.4 (0–9.4) 5.73 (3.78–12.09) <.0001
IL-2 0.6 (0–7.0) 12.16 (4.44–17.82) <.0001
IL-10 0.6 (0–3.8) 11.70 (6.87–21.32) <.0001
TNF-α 0.7 (0.1–14.3) 15.75 (7.25–27.41) <.0001
The data were expressed as median % and range.
∗∗P value for all treatment were statistically diﬀerent between patients and
healthy volunteers (<.0001).
between the increase of Th1/Th2 cytokine-producing cells
and the decrease of HBV DNA loads, ALT, AST during the
treatment (Table 4).
The levels of Th1 cytokines (IL-2, TNF-α) producing
cells in the patients without HBV mutations reached the
peaks at the 36th week of the treatment and started to drop
and maintained the levels of normal healthy individuals at
the 65th week of the treatment (Table 3). The peak of the
number ofTh2cytokine, IL-4producing cellswasat the 65th
week and started dropping to the normal individual levels
approximately at the 78th week of the treatment (Table 3).
The patient with the lamivudine resistant HBV M204V/I
mutations showed a similar Th1/Th2 cytokine response with
thenonmutationpatients; however,thepatient withadefovir
dipivoxil resistant HBV A181T/V mutations presented with
persistent lower levels of Th1/Th2 cytokines producing
CD3+CD4+ T-cells.
3.4. Serum Th1 and Th2 Cytokine Response during Adefovir
Dipivoxil Treatment. Our results have showed that the levels
of intracellular cytokines were signiﬁcantly lower in chronic
HBV patients as compared to healthy individuals at baseline
(Table 3), and increased during adefovir dipivoxil treatment
(Table 4). In order to know the Th1/Th2 cytokines better,
we further examined the same cytokines in the serum using
cytometric bead array (CBA) and analyzed the data by Chi-
Square Test. The results showed that there was a signiﬁcant
increase in the serum levels of Th1 (IL-2, IFN-γ,T N F - α)a n d
Th2 cytokines (IL-4, IL-10) in the patients after the adefovir
dipivoxil treatment as compared to the cytokine levels at the
baseline. IFN-γ showed much more increase in the response
to the adefovir dipivoxil treatment as compared to other
four cytokines. The levels of Th1/Th2 cytokines producing
cells reached the peaks at the 78th week of the treatment
and maintained up to the 104th week of the treatment
(Table6).Thelevelsandchangesofserumcytokineswerenot
associated with HBV DNA loads, ALT, and AST (P>. 05).
3.5.BiochemicalandVirologicalResponsetoAdefovirDipivoxil
Treatment. Biochemical analysis of the patients showed that
ALT and AST started to decline soon after the treatment
became normalized between 12th to 36th weeks of the
treatment and remained normal (Figure 2). Elevated serum4 Mediators of Inﬂammation
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Figure 1: Analysis of intracellular cytokine staining of IL-2, IFN-γ,T N F - α, and IL-4 from gated CD3+CD4+, respectively.
ALT and AST, however, remained in one of the patients
through the 104 weeks of adefovir dipivoxil treatment.
Serum HBsAg showed the tendency of decline.
A basal serum HBV DNA load was high in all the
patients, but decreased rapidly following the adefovir dip-
ivoxil treatment. HBV DNA load dropped to the levels
below the detection limit (<300 copies/ml), respectively, at
12 and 24 week treatment in 20 of 22 patients (Figure 2).
Two remaining patients had detectable levels of HBV DNA
throughout104weekstreatment.Theserumsamplesofthese
two patients were examined for ten HBV mutations (I169T,
V173L, L180M, A181V/T, T184G/S/A/C, A194T, S202G/I,
M204V/I, N236T, M250V) that have been reported in the
reverse transcriptase regions of HBV polymerase gene in
association with the HBV resistance to the treatment of
nucleoside and nucleotide analogs [17]. Of the two patientsMediators of Inﬂammation 5
Table 3: Th1/Th2 cytokines producing CD3+CD4+ cells in patients.
TW IL-2% CD3+CD4+ IFN-γ% CD3+CD4+ TNF-α% CD3+CD4+ IL-4% CD3+CD4+ IL-10% CD3+CD4+
TW0 0.6 (0–7.0) 0.4 (0–9.4) 0.7 (0.1–14.3) 0.4 (0–6.0) 0.6 (0–3.8)
TW12 3.9 (0.2–27.6) 3.0 (0.1–48.5) 8.6 (0.5–42.0) 6.6 (0.4–16.3) 6.5 (0.3–38.7)
TW24 11.6 (1.6–37) 22.5 (0.0–47.9) 24.7 (4.1–76.1) 17.2 (2.2–41.7) 21.0 (7.9–58.1)
TW36 14.7 (1.7–70.6) 7.4 (1.3–31.4) 22.9 (2.6–73.9) 5.9 (1.2–35.7) 19.7 (2.1–74.5)
TW52 11.4 (1.7–36.5) 19.6 (0.4–53.3) 15.5 (0.6–47.0) 34.4 (2.9–52.3) 9.6 (1.7–35.7)
TW65 10.2 (6.2–27.9) 12.5 (8.5–28.5) 8.1 (5.7–21.6) 32.9 (9.4–42.9) 7.7 (2.4–14.4)
TW78 7.6 (4.2–17.2) 9.8 (6.4–15.0) 14.9 (3.2–39.9) 13.6 (7.1–32.4) 9.7 (4.2–38.2)
TW92 14.0 (6.0–26.7) 11.9 (6.6–23.0) 26.2 (12.7–42.6) 21.1 (9.8–33.3) 12.0 (4.2–29.4)
TW104 7.4 (4.6–35.3) 14.2 (5.7–27.1) 10.8 (6.2–36.2) 10.6 (6.2–19.6) 9.4 (5.6–17.2)
∗The data were expressed as median % and range.
∗∗P value for all treatment were statistically diﬀerent from TW0 <.05.
Table 4: Correlation between intracellular Th1/Th2 cytokines and ALT, AST, HBV DNA load, and HBsAg.
IL-2% CD3+CD4+ IFN-γ% CD3+CD4+ TNF-α% CD3+CD4+ IL-4% CD3+CD4+ IL-10% CD3+CD4+
ALT
R −0.365 −0.402 −0.35 −0.386 −0.426
P< .0001 <.0001 <.0001 <.0001 <.0001
AST
R −0.376 −0.356 −0.351 −0.285 −0.461
P< .0001 <.0001 <.0001 <.0001 <.0001
HBVDNA
R −0.319 −0.382 −0.216 −0.479 −0.249
P< .0001 <.0001 0.0034 <.0001 0.007
HBsAg
R −0.245 −0.186 −0.173 −0.223 −0.152
P 0.014 0.062 0.083 0.025 0.128
Table 5: Comparison of serum cytokine in chronic HBV patients
and healthy volunteers.
Cytokine
(pg/mL) Patients (no. 22) Healthy volunteers
(no. 20) P value
IL-4 4.5 (2.2–6.5) 3.0 (1.4–14.9) 0.016∗∗
IFN-γ 5.85 (1.6–8.8) 4.4 (1.8–84.5) 0.009∗∗
IL-2 5.5 (3.5–7.3) 2.3 (0.6–10.1) 0.044∗∗
IL-10 5.7 (3.4–10.5) 1.6 (1.0–28.4) 0.499
TNF-α 2.9 (1.5–3.5) 1.6 (0.6–21.8) 0.032∗∗
∗The data were expressed as median % and range.
∗∗P value for all treatment were statistically diﬀerent between patients and
healthy volunteers (<.05).
with consistently elevated HBV DNA load (Figure 3), one
patient had HBV A181T/V mutations that are associated
with adefovir dipivoxil resistance [11] and another patient
had HBV M204V/I mutations of lamivudine resistance.
Persistently elevated serum ALT and AST were detected in
the patient with adefovir dipivoxil resistant HBV A181T/V
mutations (Figure 3). All remaining patients without HBV
mutations showed clear correlation between the decline
of HBV DNA load and the normalization of ALT and
AST through the 104 weeks of adefovir dipivoxil treatment
(Figure 2).
4. Discussion
The introduction of nucleoside and nucleotide analogs has
dramatically improved clinical management of chronic HBV
infection, a major health issue in China. Large clinical
trials of adefovir dipivoxil, in HBeAg-positive chronic HBV
patients in China have proven that adefovir dipivoxil can
signiﬁcantly improve HBV serology and liver biochemistry
after 48 and 52 weeks of treatment [18, 32]. HBeAg pur-
portedly acts via interference with Th1/Th2 cross-regulation,
and prevention of severe liver injury during adult infections
[33, 34]. However, in this study, we have examined adefovir
dipivoxil treatment of HBeAb-positive chronic HBV patients
in China and shown that after 104 weeks of the long term
treatment, twenty of twenty-two patients (90%) showed the
seroclearance of HBV DNA and normalization of ALT and
AST. These results are consistent with the earlier reports
[18, 32] and further indicate that adefovir dipivoxil is a safe
and eﬀective therapeutic agent in a long-term treatment of
chronic HBV patients in China.6 Mediators of Inﬂammation
Table 6: Serum cytokine levels in the patients following adefovir dipivoxil treatment.
IL-2 (pg/ml) IFN-γ (pg/ml) TNF-α (pg/ml) IL-4 (pg/ml) IL-10 (pg/ml)
TW0 5.5 (3.5– 7.3) 5.85 (1.6–8.8 ) 2.9 (1.5–3.5) 4.5 (2.2, 6.5) 5.7 (3.4–10.5)
TW24 6.9 (4.4–10.6) 7.6 (3.3–9.6) 3.4 (2.4–29.0) 7.6 (3.3–9.6) 7.4 (3.1–11.9)
TW52 8.4 (4.4–13.1) 13.1 (9.1–23.5) 3.3 (2.4–4.6) 7.1 (3.7–11.1) 7.4 (3.7–17.8)
TW78 9.05 (7.4–11.9) 15.8 (9.7–31.2) 4.6 (3.8–30.9) 7.9 (5.9–10.1) 7.55 (4.4–17.0)
TW104 8.6 (4.5– 11.0) 14.5 (10.0–22.5) 3.9 (3.0–6.1) 7.6 (5.3–19.6) 7.6 (5.3–19.6)
∗The data were expressed as median % and range.
∗∗P value for all treatment were statistically diﬀerent from baseline <.05.
−100
0
100
200
300
400
500
A
L
T
U
/
L
Base line 12 24 36 52 65 78 92 104
(week)
(a)
−100
0
100
200
300
400
A
S
T
U
/
L
Base line 12 24 36 52 65 78 92 104
(week)
(b)
2
3
4
5
6
7
8
H
B
V
-
D
N
A
l
o
g
1
0
c
o
p
i
e
s
(
m
L
)
Base line 12 24 36 52 65 78 92 104
(week)
(c)
1
1.5
2
2.5
3
3.5
4
4.5
H
B
S
A
G
(
I
U
/
m
L
)
Base line 24 52 78 104
(week)
(d)
Figure 2: Biochemical and virological responses after adefovir dipivoxil treatment. ALT (a), AST (b), HBV-DNA loading (c), and HBsAg
levels (d) were examined in the serum samples from chronic HBV patients at adefovir dipivoxil treatment week of 0 (baseline), 12, 24, 36,
52, 65, 78, 92, and 104 (P value for all treatment were statistically diﬀerent from baseline <.05).
In the investigation of HBV mutations in adefovir
dipivoxil resistance, we have identiﬁed HBV A181T/V muta-
tions in one and M204V/I mutations in another of two
patients that showed HBV DNA persistence through 104
weeks of adefovir dipivoxil treatment. HBV A181V/T and
N236T mutations known to adefovir dipivoxil resistance
in adefovir dipivoxil resistant patients [16, 35–37]. HBV
A181T and N236T mutations have been reported in adefovir
dipivoxil resistant patients in Taiwan [38] and Singapore
[11]. Although these mutations were not reported in an
earlierstudy of patients in China [18],wehavedetectedHBV
A181T/I mutations in one of our patients in the ChineseMediators of Inﬂammation 7
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Figure 3: Analysis of Th1/Th2 cytokine producing CD3+CD4+ cells at adefovir dipivoxil treatment week (TW) between mutation and no
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population. In addition, we have shown the persistent
elevations of HBV DNA load and ALT and AST in this
patient during adefovir dipivoxil long-term treatment. The
HBV L180M and M204V/I mutations are associated with
lamivudine resistance [17] and the concept that these
mutationscanberesponsibleforadefovirdipivoxilresistance
is intriguing and remains to be conﬁrmed in a sizable
group of adefovir dipivoxil resistant patients. A recent study
based in Hong Kong has indeed suggested that M204V/I
mutation is associated with the resistance of HBeAg-positive
chronic HBV patients to lamivudine and adefovir dipivoxil
combination treatment [39].
It is generally believed that Chronic HBV infection is
caused by the persistence of HBV covalently closed circular
DNA (cccDNA) in hepatocytes [40], in which HBV cccDNA
accumulates in the nuclei, persists as a stable episome, and
serves as a template for the HBV mRNA transcription [41].
T-cell immunity is required for the clearance of cccDNA
from hepatocytes through two immune mechanisms as
established in acute HBV infection models: CD8+ cytotoxic
T-cells clear HBV from hepatocytes through cytolysis of
infected hepatocytes and regeneration of new hepatocytes
[42] and Th1 and Th2 CD4+ T-cells-mediated humoral and
cellular immunity is able to neutralize HBV by antibodies
and inhibit HBV replication through cytokines [43]. In
contrast, however, both CD8+ and CD4+ T immunities
are functionally impaired in chronic HBV infection [21].
Here, we report that Th1 and Th2 T-cells-mediated immu-
nity, as determined by the percentage of Th1 and Th2
cytokine producing cells in peripheral blood cells, are much
weaker from chronic HBV patients than in those from
health volunteers. The impaired Th1 and Th2 immunity
are associated with the persistence of HBV load and the
elevation of ALT and AST of blood samples from chronic
HBV patients.
In the study, we have further demonstrated the inverse
correlation of the increase of Th1/Th2 cytokine producing
T-cells and the decline of HBV DNA load in blood samples
from chronic HBV patients during the long-term treatment
with adefovir dipivoxil. It is well known that both CD8+ and
CD4+ T-cell immunity are hyporesponsive in association
with persistent HBV load in serum [21], which leads
to the suggestion that high HBV load may impair T-
cell immunity and antiviral treatments can improve T-cell
immunity by reducing viral load [19]. Recent studies have
shown indeed that adefovir dipivoxil treatment leads to the
seroclearance of HBV [44] and the recovery of CD4 T-cell
immunity [24, 25]. These studies suggest the possibility that
adefovir dipivoxil, once converted intracellularly to adefovir
diphosphate, inhibits HBV DNA polymerase, thus reduces
HBV DNA load and thereby contributes to the recovery of
T-cell-mediated cellular immunity.
5. Conclusion
This study has clearly shown that the long-term treatment
with adefovir dipivoxil leads to the seroclearance of HBV
DNA, normalization of ALT and AST, response of Th1 and
Th2 cell immunity, and increase of serum Th1 and Th2
cytokines in chronic HBV patients and therefore suggested
thatadefovirdipivoxiltreatmentcontributestothereduction
of HBV DNA load and the recovery of T-cell-mediated
immunity in chronic HBV patients.
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